The Role of Cyclooxygenase Inhibitors in Cancer Prevention

Author(s): William F. Anderson, Asad Umar, Jaye L. Viner, Ernest T. Hawk

Journal Name: Current Pharmaceutical Design

Volume 8 , Issue 12 , 2002

Become EABM
Become Reviewer
Call for Editor


Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institutes (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.

Keywords: mf-tricyclio, colorectal carcinogenesis, apc, nin

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2002
Page: [1035 - 1062]
Pages: 28
DOI: 10.2174/1381612023394935
Price: $65

Article Metrics

PDF: 4